Literature DB >> 21777616

Clinical predictors of Pseudomonas aeruginosa bacteremia among Gram-negative bacterial infections in non-neutropenic patients with solid tumor.

Eun-Jeong Joo1, Cheol-In Kang, Young Eun Ha, Jungok Kim, Seung-Ji Kang, So Yeon Park, Nam Yong Lee, Yu Mi Wi, Doo Ryeon Chung, Kyong Ran Peck, Jae-Hoon Song.   

Abstract

OBJECTIVES: This study was performed to identify risk factors in Pseudomonas aeruginosa bacteremia among Gram-negative bacterial infections in non-neutropenic patients with solid tumor.
METHODS: A case-control study was performed to identify clinical predictors for P. aeruginosa bacteremia among non-neutropenic patients with Gram-negative bacteremia. Each case of P. aeruginosa bacteremia was matched to one or two controls with Escherichia coli, Klebsiella, Enterobacter or Citrobacter species in non-neutropenic patients with solid tumor.
RESULTS: Seventy-eight patients with P. aeruginosa bacteremia were compared with 98 control patients who had other Gram-negative bacteremias. The most common types of cancer were biliary tract cancer (49/176, 27.8%) and hepatocellular carcinoma (38/176, 21.6%), followed by gastric and bladder cancer. Factors associated with development of P. aeruginosa bacteremia were the presence of lung cancer, percutaneous tubes, nosocomial exposure, an invasive procedure and previous antimicrobial therapy (all P < 0.05). Independent risk factors for P. aeruginosa bacteremia included the presence of lung cancer and previous antimicrobial therapy. In the subgroup analysis including 90 patients with community-onset bacteremia, the previous use of antimicrobial agents and presence of bladder cancer were independent factors significantly associated with P. aeruginosa bacteremia.
CONCLUSIONS: Underlying lung cancer and previous antimicrobial treatment were significantly associated with P. aeruginosa bacteremia in non-neutropenic patients with solid tumor. P. aeruginosa should be considered as a probable cause of Gram-negative bacteremia in this patient group.
Copyright © 2011 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21777616     DOI: 10.1016/j.jinf.2011.06.011

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  6 in total

Review 1.  Bloodstream infections in patients with solid tumors.

Authors:  Carlota Gudiol; José María Aguado; Jordi Carratalà
Journal:  Virulence       Date:  2016-01-19       Impact factor: 5.882

2.  Emergence and prevention measures for multidrug resistant Pseudomonas aeruginosa in catheter-associated urinary tract infection in spinal cord injury patients.

Authors:  K Shigemura; R Takase; K Osawa; K Takaba; M Nomi; M Fujisawa; S Arakawa
Journal:  Spinal Cord       Date:  2014-09-02       Impact factor: 2.772

3.  Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections.

Authors:  G Samonis; K Z Vardakas; D P Kofteridis; D Dimopoulou; A M Andrianaki; I Chatzinikolaou; E Katsanevaki; S Maraki; M E Falagas
Journal:  Infection       Date:  2014-06-10       Impact factor: 3.553

4.  Outbreak of multi-drug resistant Pseudomonas aeruginosa bloodstream infection in the haematology unit of a South African Academic Hospital.

Authors:  Maanda Mudau; Rachael Jacobson; Nadia Minenza; Lazarus Kuonza; Vida Morris; Heather Engelbrecht; Mark P Nicol; Colleen Bamford
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

5.  Pseudomonas aeruginosa bacteremia in patients with liver cirrhosis: a comparison with bacteremia caused by Enterobacteriaceae.

Authors:  Ji Hwan Bang; Younghee Jung; Shinhye Cheon; Chung Jong Kim; Kyung Ho Song; Pyeong Gyun Choe; Wan Beom Park; Eu Suk Kim; Sang Won Park; Hong Bin Kim; Myoung-don Oh; Hyo-Suk Lee; Nam Joong Kim
Journal:  BMC Infect Dis       Date:  2013-07-19       Impact factor: 3.090

6.  The First Case of Pseudomonas aeruginosa Bacteremic Pneumonia in a Cancer Patient Receiving Pegfilgrastim.

Authors:  Fujiko Morita; Yuji Hirai; Kiyozumi Suzuki; Yuki Uehara; Kazunori Mitsuhashi; Masahito Takahashi; Sumio Watanabe; Toshio Naito
Journal:  Intern Med       Date:  2017-08-01       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.